International Journal of Hematology and Oncology
2025, Vol 35, Num 1 Page(s): 008-012
HYPERFACTIONED RADIOTHERAPY IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER
SEMA DURMUS1, ALİ RIZA ÜÇER1, TAMER ÇALIKOĞLU1, FAİK ÇETİNDAĞ1, OSMAN N. SUNTER1, MUZAFFER ALTUNDAĞ1
Sağlık Bakanlığı, Ankara Onkoloji Hastanesi Radyasyon Onkolojisi Kliniği, ANKARA
Keywords: lung cancer, hyperfraction, radiotherapy
Between December 1994 and September 1995 21 non-small cell lung cancer (NSCLC) patients with good performance status (Karnofsky >60 and loss of weight <%10 of body weight) treated with twice daily fractions of 120 cGy to a total dose of 6480 cGy. We observed 23.5% complete and 41.2% partial response rates. There were 23.8% acute lung toxicity rate One year and two-year overall survival rates were %52 and %16 respectively. The mean survival was 17 months. Hyperfractioned radiotherapy may be acceptable treatment modality in NSCLC patients who have good performance status.
SEMA DURMUS1, ALİ RIZA ÜÇER1, TAMER ÇALIKOĞLU1, FAİK ÇETİNDAĞ1, OSMAN N. SUNTER1, MUZAFFER ALTUNDAĞ1
Sağlık Bakanlığı, Ankara Onkoloji Hastanesi Radyasyon Onkolojisi Kliniği, ANKARA
Keywords: lung cancer, hyperfraction, radiotherapy
Between December 1994 and September 1995 21 non-small cell lung cancer (NSCLC) patients with good performance status (Karnofsky >60 and loss of weight <%10 of body weight) treated with twice daily fractions of 120 cGy to a total dose of 6480 cGy. We observed 23.5% complete and 41.2% partial response rates. There were 23.8% acute lung toxicity rate One year and two-year overall survival rates were %52 and %16 respectively. The mean survival was 17 months. Hyperfractioned radiotherapy may be acceptable treatment modality in NSCLC patients who have good performance status.